Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan J Sprengers

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of the American Academy of Child and Adolescent Psychiatry|January 15, 2021
Dr. Sprengers et al. ReplyJan J Sprengers, Dorinde M van Andel, Hilgo Bruining
Journal of Autism and Developmental Disorders|January 10, 2023
Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled TrialDorinde M van Andel, Jan J Sprengers, Marsh Königs, et al.
Molecular Autism|May 9, 2020
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot studyDorinde M van Andel, Jan J Sprengers, Bob Oranje, et al.
Frontiers in Psychiatry|February 25, 2022
Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled TrialDorinde M van Andel, Jan J Sprengers, Mandy G Keijzer-Veen, et al.
Human Mutation|June 18, 2026
Functional Analyses in Patient-Derived Neurons Establish Pathogenicity for <i>STXBP1</i> Splice Variant c.429+5G>ASylvia Korhorn, Additya Sharma, Jan J Sprengers, et al.
Translational Psychiatry|February 5, 2021
Cntn4, a risk gene for neuropsychiatric disorders, modulates hippocampal synaptic plasticity and behaviorAsami Oguro-Ando, Rosemary A Bamford, Wiedjai Sital, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 31, 2020
Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority TrialJan J Sprengers, Dorinde M van Andel, Nicolaas P A Zuithoff, et al.
Frontiers in Neuroscience|June 1, 2022
Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label StudyErika L Juarez-Martinez, Dorinde M van Andel, Jan J Sprengers, et al.
Rheumatology (Oxford, England)|December 31, 2015
Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicabilityBart V J Cuppen, Paco M J Welsing, Jan J Sprengers, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 2, 2025
Overcoming treatment implementation barriers for individuals with rare diseases using single-case experimental designsAnnelieke R Müller, Bibiche den Hollander, Agnies M van Eeghen, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of the American Academy of Child and Adolescent Psychiatry|January 15, 2021
Dr. Sprengers et al. ReplyJan J Sprengers, Dorinde M van Andel, Hilgo Bruining
Journal of Autism and Developmental Disorders|January 10, 2023
Effects of Bumetanide on Neurocognitive Functioning in Children with Autism Spectrum Disorder: Secondary Analysis of a Randomized Placebo-Controlled TrialDorinde M van Andel, Jan J Sprengers, Marsh Königs, et al.
Molecular Autism|May 9, 2020
Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot studyDorinde M van Andel, Jan J Sprengers, Bob Oranje, et al.
Frontiers in Psychiatry|February 25, 2022
Bumetanide for Irritability in Children With Sensory Processing Problems Across Neurodevelopmental Disorders: A Pilot Randomized Controlled TrialDorinde M van Andel, Jan J Sprengers, Mandy G Keijzer-Veen, et al.
Human Mutation|June 18, 2026
Functional Analyses in Patient-Derived Neurons Establish Pathogenicity for <i>STXBP1</i> Splice Variant c.429+5G>ASylvia Korhorn, Additya Sharma, Jan J Sprengers, et al.
Translational Psychiatry|February 5, 2021
Cntn4, a risk gene for neuropsychiatric disorders, modulates hippocampal synaptic plasticity and behaviorAsami Oguro-Ando, Rosemary A Bamford, Wiedjai Sital, et al.
Journal of the American Academy of Child and Adolescent Psychiatry|July 31, 2020
Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase-2 Superiority TrialJan J Sprengers, Dorinde M van Andel, Nicolaas P A Zuithoff, et al.
Frontiers in Neuroscience|June 1, 2022
Bumetanide Effects on Resting-State EEG in Tuberous Sclerosis Complex in Relation to Clinical Outcome: An Open-Label StudyErika L Juarez-Martinez, Dorinde M van Andel, Jan J Sprengers, et al.
Rheumatology (Oxford, England)|December 31, 2015
Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicabilityBart V J Cuppen, Paco M J Welsing, Jan J Sprengers, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|October 2, 2025
Overcoming treatment implementation barriers for individuals with rare diseases using single-case experimental designsAnnelieke R Müller, Bibiche den Hollander, Agnies M van Eeghen, et al.
Pageof 2